| Title |
Cariprazine: A Review in Schizophrenia
|
|---|---|
| Published in |
CNS Drugs, May 2017
|
| DOI | 10.1007/s40263-017-0442-z |
| Pubmed ID | |
| Authors |
Karly P. Garnock-Jones |
| Abstract |
Cariprazine (Vraylar™) is a dopamine D3-preferring D2/D3 receptor partial agonist indicated for the treatment of patients with schizophrenia. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the use of cariprazine in patients with this disorder. In 6-week, phase IIb and III trials in patients with schizophrenia, cariprazine was significantly more efficacious than placebo in improving schizophrenia symptoms, including improvements in Positive and Negative Syndrome Scale (PANSS) total scores. It was associated with a significantly longer time to relapse than placebo in a long-term, phase III, relapse-prevention study. Cariprazine was also significantly more efficacious than risperidone in improving PANSS Factor Score for Negative Symptoms in a phase III trial in patients with predominantly negative symptoms of schizophrenia, a typically difficult to treat group of patients. Cariprazine was generally well tolerated in clinical trials, with most adverse events being of mild to moderate severity, and metabolic changes observed were considered generally not clinically significant. Cariprazine is a useful addition to the treatment options for schizophrenia, and may be of particular use in patients with predominantly negative symptoms. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 77 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 17% |
| Other | 7 | 9% |
| Student > Bachelor | 7 | 9% |
| Student > Master | 6 | 8% |
| Researcher | 5 | 6% |
| Other | 10 | 13% |
| Unknown | 29 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 26% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 10% |
| Neuroscience | 7 | 9% |
| Psychology | 4 | 5% |
| Chemistry | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 27 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2023.
All research outputs
#7,283,695
of 22,977,819 outputs
Outputs from CNS Drugs
#665
of 1,314 outputs
Outputs of similar age
#116,205
of 316,100 outputs
Outputs of similar age from CNS Drugs
#9
of 21 outputs
Altmetric has tracked 22,977,819 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 1,314 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,100 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.